New Tech Advances Could Revolutionize the Fight Against Cancer


More than 20 million Americans benefit each year from the use of radiation to diagnose and treat a wide variety of diseases.

One such tool that has been used for more than a century in the fight against cancer is known as Brachytherapy, a form of radiation therapy where a radiation source is place inside or next to the area requiring treatment.

Experts forecast the market for Brachytherapy devices could surge to $2.4 billion by 2030, led by new technologies, applications, and markets.

Richland, Washington-based Advanced Isotope Corp. (OTC: ADMD) is one company working to commercialize such new technologies and looks poised for big upside ahead.

ADMD’s RadioGel™ device delivers Yrrium-90 particles via needle injection using a water-polymer composite, enabling high-dose treatment of tumors that cannot be treated effectively by any other means.

Designed for maximum safety, RadioGel delivers a high, pure-beta radiation dose to target (tumor) tissue, with comparatively small-to-negligible radiation doses to adjacent normal tissues, and with negligible radiation dose to any major organ or tissue in the body.

The Company is currently pursuing FDA approval to use RadioGel for the treatment of advanced basal and squamous cell skin cancers. 

In parallel to the FDA approval process, ADMD is also pursuing applications for animal cancers, where it hopes to demonstrate the safety and therapeutic effectiveness of RadioGel.

Initial results of a study at Washington State University indicate RadioGel performs as designed, confirming destruction of tumor tissue without any negative or detrimental side-effects. Contracts are being put in place to expand the testing to three other leading university veterinary hospitals.

"We are thrilled to see confirmation of RadioGel's potential," stated Dr. Mike Korenko, CEO of ADMD. "The clinical research team at WSU safely achieved near-uniform placement of RadioGel under ultrasound guidance, using the same parallel injection technique that will also be used to treat human skin cancer tumors."

It’s expected that ADMD can commercialize its pet applications more rapidly than human applications, opening the possibility of near-term revenue generation while undergoing its FDA approval process.

It’s estimated six million new cancer diagnoses are made in dogs and a similar number made in cats each year (see http://ccr.nci.nih.gov). Treating just 0.5% of these cases, at an estimated price of $5,000, would generate approximately $300 million in annual revenue annually.

Discussions are already underway two of the largest consortiums of private veterinary clinics, the Veterinary Cancer Group (VCG) and VCA Inc. 

VCG has 55 veterinary centers feeding into three specialty clinics. VCA has 820 clinics in the US and Canada feeding into approximately 25 specialty treatment centers.

ADMD expects the majority of its animal study testing to be completed in the first quarter of 2018.

Learn more about this exciting opportunity by watching our exclusive interview with ADMD founder and CEO, Dr. Mike Korenko.


Watch Exclusive Interview




"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market